Role of pirfenidone in the management of pulmonary fibrosis
Authors:
Open Access
- 1 April 2017
- journal article
- review article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 13, 427-437
Abstract
Pulmonary fibrosis is associated with a number of specific forms of interstitial lung disease (ILD) and can lead to progressive decline in lung function, poor quality of life, and, ultimately, early death. Idiopathic pulmonary fibrosis (IPF), the most common fibrotic ILD, affects up to 1 in 200 elderly individuals and has a median survival that ranges from 3 to 5 years following initial diagnosis. IPF has not been shown to respond to immunomodulatory therapies, but recent trials with novel antifibrotic agents have demonstrated lessening of lung function decline over time. Pirfenidone has been shown to significantly slow decline in forced vital capacity (FVC) over time and prolong progression-free survival, which led to its licensing by the United States Food and Drug Administration (FDA) in 2014 for the treatment of patients with IPF. However, pirfenidone has been associated with significant side effects, and patients treated with pirfenidone must be carefully monitored. We review recent and ongoing clinical research and experience with pirfenidone as a pharmacologic therapy for patients with IPF, provide a suggested approach to incorporate pirfenidone into a treatment algorithm for patients with IPF, and examine the potential of pirfenidone as a treatment for non-IPF forms of ILD accompanied by progressive pulmonary fibrosis.Keywords
This publication has 59 references indexed in Scilit:
- Precision Medicine: The New Frontier in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisThorax, 2016
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsEuropean Respiratory Journal, 2015
- Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPFEuropean Respiratory Journal, 2015
- Idiopathic pulmonary fibrosis: from clinical trials to real-life experiencesEuropean Respiratory Review, 2015
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Predicting Survival Across Chronic Interstitial Lung DiseaseChest, 2014
- A Multidimensional Index and Staging System for Idiopathic Pulmonary FibrosisAnnals of Internal Medicine, 2012
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus StatementAmerican Journal of Respiratory and Critical Care Medicine, 2000